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IMPORTANCE High-sensitivity cardiac troponin I testing is widely used to evaluate patients
with suspected acute coronary syndrome. A cardiac troponin concentration of less than
5 ng/L identifies patients at presentation as low risk, but the optimal threshold is uncertain.
OBJECTIVE To evaluate the performance of a cardiac troponin I threshold of 5 ng/L at
presentation as a risk stratification tool in patients with suspected acute coronary syndrome.
DATA SOURCES Systematic search of MEDLINE, EMBASE, Cochrane, andWeb of Science
databases from January 1, 2006, to March 18, 2017.
STUDY SELECTION Prospective studies measuring high-sensitivity cardiac troponin I
concentrations in patients with suspected acute coronary syndrome in which the diagnosis
was adjudicated according to the universal definition of myocardial infarction.
DATA EXTRACTION AND SYNTHESIS The systematic review identified 19 cohorts. Individual
patient-level data were obtained from the corresponding authors of 17 cohorts, with
aggregate data from 2 cohorts. Meta-estimates for primary and secondary outcomes were
derived using a binomial-normal random-effects model.
MAIN OUTCOMES ANDMEASURES The primary outcomewasmyocardial infarction or cardiac
death at 30 days. Performance was evaluated in subgroups and across a range of troponin
concentrations (2-16 ng/L) using individual patient data.
RESULTS Of 11 845 articles identified, 104 underwent full-text review, and 19 cohorts from 9
countries were included. Among 22 457 patients included in themeta-analysis (mean age, 62
[SD, 15.5] years; n = 9329women [41.5%]), the primary outcome occurred in 2786 (12.4%).
Cardiac troponin I concentrations were less than 5 ng/L at presentation in 11 012 patients
(49%), in whom there were 60missed index or 30-day events (59 indexmyocardial
infarctions, 1 myocardial infarction at 30 days, and no cardiac deaths at 30 days). This
resulted in a negative predictive value of 99.5% (95% CI, 99.3%-99.6%) for the primary
outcome. There were no cardiac deaths at 30 days and 7 (0.1%) at 1 year, with a negative
predictive value of 99.9% (95% CI, 99.7%-99.9%) for cardiac death.
CONCLUSIONS AND RELEVANCE Among patients with suspected acute coronary syndrome,
a high-sensitivity cardiac troponin I concentration of less than 5 ng/L identified those at low
risk of myocardial infarction or cardiac death within 30 days. Further research is needed to
understand the clinical utility and cost-effectiveness of this approach to risk stratification.
JAMA. 2017;318(19):1913-1924. doi:10.1001/jama.2017.17488
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C hest pain is one of the most common reasons forpresentation to hospitals worldwide.1 Despite themajority of patients not having myocardial infarc-
tion,2 hospital admission for observation and serial car-
diac troponin testing is required in many patients to identify
those with and without myocardial infarction.3 Novel
strategies to identify low-risk patients at presentation
have been proposed to reduce hospital admissions, serial
testing, and resource utilization as well as to improve care
for patients.4,5
High-sensitivity assays are able to quantify cardiac
troponin at low concentrations and provide an opportunity
to rule out myocardial infarction at an earlier stage. In a pro-
spective study of consecutive patients with suspected acute
coronary syndrome, a risk stratification threshold was
defined using a high-sensitivity cardiac troponin I assay.
In 4870 patients, a threshold of less than 5 ng/L had a nega-
tive predictive value (NPV) of 99.6%, misclassifying less
than 1 myocardial infarction for every 200 patients tested.6
This threshold identified more than half of all patients
with suspected acute coronary syndrome as low risk, reduc-
ing the proportion of patients who require admission for
serial testing.7
Recent studies have questioned whether 5 ng/L is the
optimal threshold to risk-stratify patients and have proposed
alternative thresholds that may miss fewer patients with
myocardial infarction.8-11 To investigate these concerns, a
systematic review of all studies of high-sensitivity cardiac
troponin I testing in patients with suspected acute coronary
syndrome was undertaken and individual patient-level data
were obtained. Across multiple cohorts with varying preva-
lence of myocardial infarction, the aim was to evaluate the
performance of this threshold, to evaluate other risk stratifi-
cation thresholds, and to determine the association with
other clinical risk characteristics.
Methods
Search Strategy and Selection of Articles
A systematic search of the MEDLINE, EMBASE, Cochrane,
and Web of Science databases was performed without lan-
guagerestriction fromJanuary1,2006, toMarch18,2017,using
detailed search terms for chest pain, acute coronary syn-
drome, acute myocardial infarction, troponin, high sensitive/
sensitivity, and emergency department (Figure 1; eAppendix 1
in the Supplement contains the full search strategy). Stud-
ies were included if they met the following prespecified
eligibility criteria: (1) were prospective studies of patients in-
vestigated in the emergency department for suspected acute
coronary syndrome; (2) measured cardiac troponin using the
Abbott ARCHITECTSTAT high-sensitive cardiac troponin I
assay (Abbott Laboratories) at presentation; and (3) hadanad-
judicated end point of myocardial infarction on index hospi-
talization (eAppendixes 2 and 3 in the Supplement). All find-
ings are reported in accordance with the Preferred Reporting
Items for Systematic Review andMeta-analysis of Individual
Participant Data (PRISMA-IPD).12
Data Extraction
Two investigators (A.R.C. and K.K.L.) performed the initial
screening of titles and abstracts. Full-text reports of poten-
tially relevant articles were obtained and assessed by both
investigators using a prespecified protocol (PROSPERO reg-
ister CRD42017059128). A third investigator (A.S.V.S.) adju-
dicated all disagreements. When there were multiple
articles describing the same cohort, the article that included
the largest number of participants was included. The corre-
sponding authors of each eligible cohort were contacted
with a request for anonymized data including cardiac tro-
ponin concentrations, adjudicated diagnosis, outcomes,
and prespecified covariates (age, sex, chest pain, time from
symptom onset to presentation sample, myocardial ische-
mia on electrocardiogram, cigarette smoking, diabetes
mellitus, hypertension, hyperlipidemia, known angina, pre-
vious myocardial infarction, percutaneous coronary inter-
vention, coronary artery bypass graft surgery, and stroke).
All studies were prospective and conducted in accordance
with the Declaration of Helsinki with approval from the
regional ethics committee or institutional review board, and
written consent was obtained where required. This approval
permitted each contributor to share individual-level data or
aggregate data for inclusion in this meta-analysis. Bias was
assessed by 2 investigators independently, with consensus
from a third, using the Quality Assessment of Diagnostic
Accuracy Studies version 2 (QUADAS-2) framework (eAp-
pendix 4 in the Supplement).
Analysis Population and Primary Outcome
The analysis population comprised patients with cardiac
troponin concentrations at or below the 99th percentile at
presentation (those above the 99th percentile have evi-
dence of myocardial injury and are not eligible for risk
stratification at presentation). Patients with ST-segment
elevation myocardial infarction and those who presented in
cardiac arrest were excluded from this analysis. The pre-
specified primary outcome was a composite of type 1 myo-
cardial infarction or cardiac death at 30 days. The prespeci-
fied secondary outcomes were recurrent myocardial
infarction and cardiac death at 1 year. In addition, we evalu-
ated the performance of cardiac troponin thresholds for the
Key Points
Question What is the optimal high-sensitivity cardiac troponin I
concentration at presentation to risk-stratify patients with
suspected acute coronary syndrome?
Findings In an individual patient-level meta-analysis of 22 457
patients from 9 countries, troponin I concentrations were less
than 5 ng/L in 49%, among whom 5 per 1000 patients had a
myocardial infarction or cardiac death at 30 days.
Meaning Among patients with suspected acute coronary
syndrome, a high-sensitivity cardiac troponin I threshold of
less than 5 ng/L identified patients at low risk of cardiac
events; further research is needed to assess the clinical utility
of this test.
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diagnosis of type 1 or type 2 myocardial infarction on index
presentation. The number of patients available for each
analysis is shown in Figure 1.
Statistical Analysis
Baseline characteristics are summarized as mean (standard
deviation) or median (interquartile range) as appropriate.
The primary outcome measure was the NPV of a high-
sensitivity cardiac troponin I concentration of less than
5 ng/L at presentation. All cardiac troponin concentrations
were rounded to integer values in line with clinical stan-
dards for reporting. When individual patient-level data were
available, this was checked for consistency and complete-
ness, and cohort-level summary counts of patients with and
without the primary outcome were derived for a high-
sensitivity cardiac troponin I concentration of less than
5 ng/L at presentation. In cohorts in which raw data were
not available, the corresponding authors were asked to pro-
vide these summaries. The NPV was calculated at a cohort
level using a Bayesian approach, with a binomial likelihood
and beta prior (a noninformative Jeffreys prior with both
shape parameters equal to 0.5), as this produces confidence
intervals with better coverage when proportions are close to
0 or 1.13 Heterogeneity is reported using the I2 statistic.14
Survival free from cardiac death at 30 days and at 1 year is
reported for patients with cardiac troponin I concentrations
of less than 5 ng/L, 5 ng/L to the 99th percentile, and greater
than the 99th percentile at presentation.
Figure 1. Flow of the Study Population and Data Analysis
416 Duplicate articles removedb
11 845 Articles identified through
database searcha
11 325 Excluded (did not meet
 eligibility criteria)
11 429 Article titles and abstracts
screened for eligibility
68 Excluded (did not meet
inclusion criteria)c
104 Full-text articles assessed
for eligibility
18 601 Participants with individual patient-
level data
18 601 Included in evaluation of
additional cardiac troponin
thresholds (2-16 ng/L)
15 672 Had available
electrocardiogram data
12 953 Included in evaluation of cardiac
death at 30 d
9271 Included in evaluation of cardiac
death at 1 y
17 Cohorts had individual patient-level
data available (18 601 total participants)
2 Cohorts had aggregate data available
(3856 total participants)
36 Articles included (19 unique cohorts)
18 248 Included in analysis population
(patients with cardiac troponin
concentrations ≤99th percentile
at presentation) for primary
outcome of myocardial infarction
of cardiac death and subgroup
analysese
16 537 Included in analysis of secondary
outcome of index non–ST-segment
myocardial infarction
22 457 Participants with individual patient-level
or aggregate datad
Flow diagram illustrating the systematic database review and screening of
articles, level of exclusion, the number of articles included, and the individual
patient-level data or aggregate data available for each analysis, based on the
PRISMA-IPD guidelines.12
a Articles identified through a systematic database search: MEDLINE = 2078;
EMBASE = 7116; Cochrane = 390;Web of Science = 2261.
bAny identical publications were removed, but articles from the same cohorts
were retained at this stage.
c Articles excluded after full-text reviewbecause they evaluated a contemporary
cardiac troponin I assay (n = 36), a different high-sensitivity cardiac troponin I
assay (n = 14), a high-sensitivity cardiac troponin T assay (n = 5), a different
patient population (n = 4), or a different outcomemeasure (n = 9).
dAuthors who did not provide individual patient-level data provided aggregate
data for the primary outcome, subgroup analyses, and secondary outcome
when available.
e Subgroup analyses were prespecified, with the following data available per
group: age (n = 18 248), sex (n = 18 248), diagnosis of ischemic heart disease
(n = 14 160), time from symptom onset to troponin sample time (n = 13 404),
and electrocardiogram (n = 15 887).
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Prespecified Subgroup Analyses
For the primary outcome, the NPV was evaluated in pre-
specified subgroups stratified by age (≤65 or >65 years), sex,
history of ischemic heart disease, time since symptom onset
(≤2 or >2 hours), and presence of myocardial ischemia on
electrocardiogram. Most cohorts defined myocardial ische-
mia as at least 2-mm ST-segment depression in 2 consecu-
tive leads or new T-wave inversion. To explore the clinical
implications of differences in performance between sub-
groups, we undertook these subgroup analyses in patients
without myocardial ischemia on electrocardiogram. Studies
have demonstrated imperfect calibration between high-
sensitivity cardiac troponin I and T assays, with up to 17.5%
of patients greater than the 99th percentile on the T assay
shown to be less than the 99th percentile on the I assay.15
Therefore, a further analysis evaluated whether the assay
used to adjudicate the index diagnosis affected the perfor-
mance of the risk stratification threshold. In addition, we
determined whether the assessed risk of bias and site of
patient recruitment affected the NPV.
Derivation ofMeta-estimates
Meta-estimates of the NPV were derived in the analy-
sis population for all primary and secondary outcomes by
modeling cohort-level proportions (true negative/[true
negative + false negative]) in a binomial-normal random-
effects model, with an additional term when cohort-level
characteristics (adjudication assay, assessment of bias or
location of recruitment) were compared. We estimated
odds ratios for the difference in NPV between prespecified
subgroups, meta-analyzing this across cohorts to ob-
tain the mean odds ratio and a P value for the null hypoth-
esis of no association. For cohorts in which individual
patient-level data were available, the cardiac troponin
threshold that would identify the highest proportion of
patients as at low risk for an NPV at or above 99.5% was
determined. For this analysis, we prespecified an NPV of
99.5% as being clinically acceptable and equivalent to a
miss rate of 5 per 1000 low-risk patients.16 To evaluate how
the inclusion of a risk stratification threshold would affect
the overall diagnosis in all patients with suspected acute
coronary syndrome, meta-estimates of NPV, positive predic-
tive value (PPV), and sensitivity were derived for risk strati-
fication thresholds alone (2-16 ng/L) and in conjunction
with a nonischemic electrocardiogram result at presenta-
tion. At each threshold, the proportion of the total popula-
tion classified as low risk and the miss rate per 1000
patients was reported. All analyses were performed in R ver-
sion 3.2.2, with the meta-analyses performed using the
metafor package.17 The analysis code is available online
(eAppendix 5 in the Supplement).
Results
Systematic Review
The initial search identified 11 845 articles, of which 104
articles underwent full-text review. A total of 36 articles met
inclusion criteria, reporting observations from 19 individual
cohorts across 9 different countries (Figure 1). Five articles
reported outcomes for a high-sensitivity cardiac troponin I
concentration of less than 5 ng/L.6,8-10,18
Study Population
All corresponding authors from the 19 individual cohorts
identified in the systematic review agreed to provide data
for the meta-analysis. Individual patient-level data were
obtained from 17 cohorts6-9,11,18-29 and aggregate data from 2
cohorts,10,30 for a total study population of 22 457 patients
with suspected acute coronary syndrome (mean age, 62 [SD,
16] years; 41.5% women) (Table 1, Table 2, and Table 3). In 11
cohorts, data were available for the prespecified primary out-
come of type 1 myocardial infarction or cardiac death at
30 days (Table 4). In the remainder, the outcome was index
type 1 myocardial infarction (n = 1) or non–ST-segment eleva-
tion myocardial infarction on index presentation (n = 5) or
at 30 days (n = 2). The assessed risk of bias was high in 11
cohorts because of patient selection or use of a contemporary
reference standard (eAppendixes 3 and 4 in the Supplement).
Across all cohorts, the proportion with the primary outcome
was 12.4% (range, 2.4%-24.0%). The analysis population
comprised 18248 of 22457 patients in which high-sensitivity
cardiac troponin I concentrations were below the 99th per-
centile at presentation, and the prevalence of the primary
outcome was 3.5% (range, 0.6%-6.1%).
Meta-estimate of the Risk Stratification Threshold
High-sensitivity cardiac troponin I concentrations were less
than 5 ng/L at presentation in 11 012 patients (49%), with an
NPV of 99.5% (95% CI, 99.3%-99.6%) (Figure 2 and Table 2)
for the primary outcome and a total of 60 missed index or
30-day events (59 index myocardial infarctions, 1 myocar-
dial infarction at 30 days, and no cardiac deaths at 30 days)
(eTable 1 in the Supplement). The NPV was similar across
cohorts with varying prevalence of myocardial infarction.
The estimate of heterogeneity (I2) was 31.9%. Cohort-level
2×2 summary tables are provided for the analysis popula-
tion in eTable 2 in the Supplement. When data were avail-
able in the analysis population (n = 16 537 [90.6%]), we
estimated the NPV for the secondary outcome of index
non–ST-segment elevation myocardial infarction (type 1 or
type 2 myocardial infarction). Cardiac troponin I concentra-
tions were less than 5 ng/L at presentation in 9574 patients
(48%), with an NPV of 99.4% (95% CI, 99.2%-99.6%) and
a total of 58 missed events.
Subgroup Analysis
Meta-estimates of NPV were obtained in a number of pre-
specified subgroups (Figure 3). The NPV was lower in those
with (98.2%; 95% CI, 96.4%-99.1% [n = 2178]) compared
with those without (99.7%; 95% CI, 99.4%-99.8%
[n = 13 709]) myocardial ischemia on electrocardiogram
(P < .001) and in those who presented within 2 hours of
symptom onset (99.0% [95% CI, 97.7%-99.5%] [n = 2303] vs
99.6% [95% CI, 99.4%-99.8%] [n = 11 101]; P = .003). Differ-
ences in the NPV were also observed between patients older
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than 65 years (NPV, 99.1%; 95% CI, 98.5%-99.5% [n = 6818])
compared with those aged 65 years or younger (99.6%; 95%
CI, 99.4%-99.8% [n = 11 430]; P = .02) and in those with
(NPV, 98.8%; 95% CI, 98.1%-99.3% [n = 3990]) compared
with those without (NPV, 99.6%; 95% CI, 99.4%-99.7%
[n = 10 170]) a history of ischemic heart disease (P = .03).
When this analysis was restricted to patients without myo-
cardial ischemia on electrocardiogram, estimates of NPV
were higher than 99% for all subgroups (eFigure 1 in the
Supplement). Performance of the risk stratification threshold
was similar regardless of the assay used for adjudication
(high-sensitivity cardiac troponin I: NPV, 99.6% [95% CI,
99.3%-99.7%] [n = 7046]; contemporary cardiac troponin I
or T: NPV, 99.6% [95% CI, 99.3%-99.7%] [n = 5907]; high-
sensitivity cardiac troponin T: NPV, 99.2% [95% CI, 98.6%-
99.6%] [n = 5295]; P = .27), the assessed risk of bias (high risk
of bias: NPV, 99.5% [95% CI, 99.1%-99.7%] [n = 7043]; low
risk of bias: NPV, 99.3% [95% CI, 99.3%-99.6%] [n = 11 205];
P = .37), and the site of patient recruitment (Europe: NPV,
99.5% [95% CI, 99.1%-99.7%] [n = 11 714]; North America:
NPV, 99.5% [95% CI, 99.0%-99.8%] [n = 2999]; Asia-Pacific:
NPV, 99.5% [95% CI, 99.1%-99.7%] [n = 3535]; P = .30) (eFig-
ure 2 in the Supplement).
Short- and Long-termOutcomes
According to the Risk Stratification Threshold
Follow-up data for cardiac death at 30 days and at 1 year
were available in 12 953 patients (57.7%) and 9271 patients
(41.3%), respectively (eTables 3 and 4 in the Supplement).
In patients with cardiac troponin concentrations of less than
5 ng/L at presentation (n = 6956), there were no cardiac
deaths at 30 days (NPV, 100% [95% CI, 99.9%-100%]; sensi-
tivity, 99.4% [95% CI, 97.7%-100%]) and 7 cardiac deaths
(0.1%) at 1 year (NPV, 99.9% [95% CI, 99.7%-99.9%]; sensi-
tivity, 96.1% [95% CI, 92.9%-98.3%]). In patients with car-
diac troponin concentrations between 5 ng/L and the 99th
percentile at presentation (n = 3817), there were 19 cardiac
deaths at 30 days (0.5%) and 58 (2.1%) at 1 year. In compari-
son, in those with troponin concentrations above the 99th
percentile (n = 2180), there were 62 cardiac deaths at 30
days (2.8%) and 125 (8.2%) at 1 year. In patients with tro-
ponin concentrations of less than 5 ng/L at presentation and
an index or 30-day myocardial infarction, there were no car-
diac deaths at 30 days or at 1 year. Because the majority of
studies did not adjudicate recurrent myocardial infarction
events at 1 year, we were not able to conduct this prespeci-
fied analysis.
Table 1. Baseline Characteristics of All Study Patients and High-Sensitivity Cardiac Troponin I Cohorts
Characteristics
All Patients
(N = 22 457)
High STEACS-V6
(n = 4701)
UTROPIA10
(n = 1630)
High STEACS-P19
(n = 1064)
High STEACS-S7
(n = 756a)
EDACS20
(n = 558)
Age, mean (SD), y 62 (15.5)b 63.7 (16.3) 57.5 (15.3) 65.6 (15.9) 62 (14.2) 59.2 (11.9)
Male, No. (%) 13 128 (58.5) 2651 (56.4) 911 (55.9) 579 (54.4) 462 (61.1) 340 (60.9)
Chest pain, No. (%) 16 760 (80.2) 3917 (83.3) 835 (51.2) 880 (82.9) 651 (86.1) 558 (100)
Time from symptom onset
to troponin sample,
median (IQR), min
355 (172-794) 454 (255-814) 352 (114-590) NA 244 (146-644) 210 (115-501)
Myocardial ischemia on ECG,
No. (%)
3663 (18.8) 795 (19.5) 126 (7.7) 326 (31.6) 84 (12.3) 25 (4.5)
Cardiovascular risk factors, No. (%)
Hypertension 11 018 (54.3) 1376 (33.3) 1074 (65.9) 570 (53.6) 327 (45.0) 290 (52)
Hyperlipidemia 9270 (45.7) 1113 (27.0) 696 (42.7) 484 (45.7) 291 (40.3) 284 (50.9)
Smoker 6093 (32.6) 842 (32.1) 592 (36.3) 255 (26.2) 149 (20.3) 84 (15.1)
Diabetes 3703 (18.3) 661 (16.0) 505 (31.0) 173 (16.2) 115 (15.6) 78 (14)
Known angina 4299 (28.7) 1379 (33.3) 264 (16.2) 451 (42.5) 220 (29.8) 139 (24.9)
Previous myocardial
infarction
4319 (21.3) 785 (19.0) 190 (11.7) 284 (26.7) 161 (21.9) 130 (23.3)
Previous PCI 2521 (15.6) 439 (10.6) 150 (9.2) 162 (15.2) 132 (18.1) NA
Previous CABG surgery 1536 (8.4) 242 (5.9) 73 (4.5) 83 (7.8) 37 (5.1) 26 (4.7)
Previous stroke 1603 (8.1) 333 (8.1) 153 (9.4) 136 (12.8) 40 (5.6) NA
High-sensitivity cardiac troponin percentile at presentation, No. (%)
≤99th 18 248 (81.3) 3781 (80.4) 1326 (81.3) 828 (77.8) 617 (81.6) 494 (88.5)
>99th 4209 (18.7) 920 (19.6) 304 (18.7) 236 (22.1) 139 (18.4) 64 (11.5)
Abbreviations: CABG, coronary artery bypass graft; ECG, electrocardiogram;
EDACS, Emergency Department Assessment of Chest Pain Score;
High STEACS-P, High-Sensitivity Cardiac Troponin in the Evaluation of Patients
With Suspected Acute Coronary Syndrome–Pilot; High STEACS-S;
High-Sensitivity Cardiac Troponin in the Evaluation of Patients With Suspected
Acute Coronary Syndrome–Substudy; High STEACS-V; High-Sensitivity Cardiac
Troponin in the Evaluation of Patients With Suspected Acute Coronary
Syndrome–Validation; IQR, interquartile range; NA, data not available;
PCI, percutaneous coronary intervention; UTROPIA, Use of Abbott High
Sensitivity Cardiac Troponin I Assay in Acute Coronary Syndromes.
a Only unique patients from the High STEACS-S cohort are included.
b Summary estimates for age and sample time exclude UTROPIA and APACE
(Advantageous Predictors of Acute Coronary Syndromes Evaluation) because
only aggregate data were available.
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Table 2. Baseline Characteristics of Contemporary Cardiac Troponin I and T Cohorts
Characteristics
Keller et al21
(n = 1598)
ADAPT-B22
(n = 804)
IMPACT23
(n = 1127)
ROMI18
(n = 1137)
Korley et al24
(n = 808)
ADAPT-C25
(n = 1106)
ADAPT-RCT26
(n = 474)
RING27
(n = 144)
Age, mean (SD), y 61.3 (13.6) 55.2 (15.2) 51.2 (12.6) 66.7 (16.5) 56.6 (13.3) 65.3 (13.0) 60.7 (12.6) 59.7 (13.7)
Male, No. (%) 1046 (65.5) 482 (60.0) 676 (60.0) 535 (47.1) 381 (47.2) 659 (59.6) 297 (62.7) 93 (64.6)
Chest pain, No. (%) 833 (52.1) 690 (85.8) 844 (74.9) 651 (57.3) 479 (59.3) 1106 (100) 474 (100) 134 (93.1)
Time from
symptom onset
to troponin sample,
median (IQR), min
295 (150-833) 330 (130-1275) 216 (110-676) NA 669 (348-750) 390 (210-785) 300 (180-525) 210 (140-275)
Myocardial ischemia
on ECG, No. (%)
855 (54.1) 51 (6.3) 36 (3.2) NA NA 188 (17.0) 21 (4.4) NA
Cardiovascular risk factors, No. (%)
Hypertension 1190 (74.5) 403 (50.1) 447 (39.7) 804 (71.2) 509 (63) 679 (61.4) 214 (45.1) 92 (64.3)
Hyperlipidemia 1178 (73.7) 386 (48) 427 (37.9) 676 (60.6) 340 (42.1) 636 (57.5) 243 (51.3) 79 (56.4)
Smoker 362 (22.8) 188 (23.4) 276 (24.5) 700 (61.6) 290 (35.9) 161 (14.6) 85 (17.9) 95 (66.4)
Diabetes 246 (15.7) 107 (13.3) 141 (12.5) 333 (29.7) 240 (29.7) 178 (16.1) 70 (14.8) 36 (25.9)
Known angina NA 188 (23.4) 125 (11.1) 305 (27.5) 168 (20.8) 527 (47.6) 100 (21.1) 60 (41.7)
Previous MI 363 (23.2) 138 (17.2) 130 (11.5) 408 (36.6) 153 (18.9) 334 (30.2) 121 (25.5) 52 (36.4)
Previous PCI 335 (25.8) 87 (10.8) 85 (7.5) 251 (22.4) 112 (13.9) NA NA NA
Previous CABG surgery 165 (14.7) 55 (6.8) 44 (3.9) 251 (22.4) 61 (7.5) 122 (11.0) 37 (7.8) 46 (32.2)
Previous stroke 87 (5.5) 74 (9.2) 46 (4.1) 190 (17.0) 117 (14.5) 65 (5.9) 47 (9.9) 11 (7.7)
Cardiac troponin concentration percentile at presentation, No. (%)
≤99th 1193 (74.7) 720 (89.6) 1083 (96.1) 915 (80.5) 636 (78.7) 838 (75.8) 400 (84.4) 122 (84.7)
>99th 405 (25.3) 84 (10.4) 44 (3.9) 222 (19.5) 172 (21.3) 268 (24.2) 74 (15.6) 22 (15.3)
Abbreviations: ADAPT, 2-h Accelerated Diagnostic Protocol to Assess Patients
With Chest Pain Symptoms Using Contemporary Troponins as the Only
Biomarker; CABG, coronary artery bypass graft; ECG, electrocardiogram;
IMPACT, Improved Assessment of Chest Pain Trial; IQR, interquartile range;
MI, myocardial infarction; NA, data not available; PCI, percutaneous coronary
intervention; RCT, randomized clinical trial; RING, Reducing the Time Interval
for Identifying New Guideline; ROMI, Rule Out of Myocardial Infarction.
Table 3. Baseline Characteristics of High-Sensitivity Cardiac Troponin T Cohorts
Characteristics
TI-AMO11
(n = 1552)
APACE30
(n = 2226)
BACC9
(n = 1496)
TRUST8
(n = 867)
Body et al28
(n = 229)
Body et al29
(n = 180)
Age, mean (SD), y 67.2 (16.0) 62 (16.0) 62.6 (15.7) 57.9 (13.1) 65.4 (15.6) 57.2 (14.5)
Male, No. (%) 781 (50.3) 1512 (67.9) 955 (63.8) 515 (59.4) 137 (59.8) 116 (64.4)
Chest pain, No. (%) NA 2226 (100) 1206 (80.7) 867 (100) 229 (100) 180 (100.0)
Time from symptom onset
to troponin sample,
median (IQR), min
NA 300 (120-720) NA 179 (119-349) 189 (96-513)a 197 (84-333)a
Myocardial ischemia on ECG,
No. (%)
156 (10.5) 476 (21.4) 430 (29.4) 0 48 (21.0) 46 (25.6)
Cardiovascular risk factors, No. (%)
Hypertension NA 1383 (62.1) 1015 (68.2) 477 (55.0) 93 (40.6) 75 (41.9)
Hyperlipidemia NA 1111 (49.9) 592 (39.6) 583 (67.2) 91 (39.7) 60 (33.3)
Smoker NA 1370 (61.5) 352 (23.6) 210 (24.2) 36 (15.7) 46 (26.9)
Diabetes NA 405 (18.2) 201 (13.6) 145 (16.7) 42 (18.3) 27 (15.0)
Known angina NA NA NA 223 (25.7) 97 (42.4) 53 (29.6)
Previous myocardial infarction NA 514 (23.1) 240 (16.1) 190 (21.9) 78 (34.1) 48 (27.0)
Previous PCI NA 527 (23.7) NA 168 (19.4) 34 (14.8) 39 (21.8)
Previous CABG surgery NA 211 (9.5) NA 41 (4.7) 30 (13.1) 12 (6.8)
Previous stroke NA 122 (5.5) 102 (6.8) 57 (6.6) 20 (8.7)b 3 (1.7)b
High-sensitivity cardiac troponin percentile at presentation, No. (%)
≤99th 1156 (74.5) 1801 (80.9) 1202 (80.3) 810 (93.4) 179 (78.2) 147 (81.7)
>99th 396 (25.5) 425 (19.1) 294 (19.7) 57 (6.6) 50 (21.8) 33 (18.3)
Abbreviations: APACE, Advantageous Predictors of Acute Coronary
Syndromes Evaluation; BACC, Biomarkers in Acute Cardiovascular Care;
CABG, coronary artery bypass graft; ECG, electrocardiogram;
IQR, interquartile range; NA, data not available; PCI, percutaneous
coronary intervention; TRUST, Triage Rule-Out Using High-Sensitivity
Troponin.
a Only symptom to presentation time available.
b Includes patients with transient ischemic attack.
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Risk Stratification Thresholds and Diagnosis
of Myocardial Infarction
In all patients with suspected acute coronary syndrome for
whom individual patient-level data were available (n = 18601
[82.8%]), we evaluated how different risk stratification
thresholds would affect the NPV and sensitivity for the pri-
mary outcome. When used in isolation, a troponin I concen-
tration of less than 5 ng/L gave an NPV of 99.5% (95% CI,
99.3%-99.7%) and a sensitivity of 98.0% (95% CI, 96.4%-
98.9%), identifying 49.1% of patients as low risk with a miss
rate of 5.4 (95% CI, 4.0-7.0) per 1000 patients. At a threshold
of less than 2 ng/L, the NPV was 99.8% (95% CI, 99.0%-
100%) and the sensitivity was 100% (95% CI, 98.9%-100%),
but the proportion of patients identified as low risk was lower
at 13.7%. Although the absolute number of missed cases was
lower, the miss rate was similar at 4.1 (95% CI, 2.0-6.9) per
1000 patients (eTable 5 in the Supplement).
In a subgroup analysis combining risk stratification
thresholds and a nonischemic electrocardiogram result
(Figure 4), a cardiac troponin I concentration of less than
5 ng/L gave an NPV of 99.7% (95% CI, 99.4%-99.8%) and a
sensitivity of 99.0% (95% CI, 97.3%-99.6%), identifying
Table 4. Summary of Cohort Size, End Points, and Prevalence ofMyocardial Infarction
Cohorts
Cohort Size,
No. Primary Outcome
Prevalence of Primary
Outcome, No. (%)
Assay Used for MI
Adjudication NPV, % (95% CI)
hs-cTnI <5 ng/L at
Presentation, No. (%)
of Total CohortTotal Cohort
≤99th
Percentilea
High-Sensitivity Cardiac Troponin I Cohorts
High STEACS-V6 4701 Type 1 MI or cardiac
death (30 d)
662 (14.1) 141 (3.7) Abbott hs-cTnI 99.6 (99.3-99.8) 2292 (48.8)
UTROPIA10 1630 Type 1 MI or cardiac
death (30 d)
70 (4.3) 22 (1.4) Abbott hs-cTnI 99.5 (99.0-99.9) 774 (47.5)
High STEACS-P19 1064 Type 1 MI or cardiac
death (30 d)
201 (18.9) 46 (5.6) Abbott hs-cTnI 99.7 (99.0-100) 469 (44.1)
High STEACS-S7 756 Type 1 MI or cardiac
death (30 d)
115 (15.2) 25 (4.1) Abbott hs-cTnI 99.4 (98.5-99.9) 428 (56.6)
EDACS20 558 Type 1 MI or cardiac
death (30 d)
66 (11.8) 17 (3.4) Abbott hs-cTnI 99.1 (97.9-99.8) 378 (67.7)
Contemporary Cardiac Troponin I and T Cohorts
Keller et al21 1598 Index NSTEMI 268 (16.8) 29 (2.4) Roche cTnT 99.9 (99.7-100) 563 (35.2)
ADAPT-B22 804 Type 1 MI or cardiac
death (30 d)
48 (6.0) 8 (1.1) Beckmann Accu-cTnI 99.7 (99.1-100) 532 (66.2)
IMPACT23 1127 Type 1 MI or cardiac
death (30 d)
49 (4.3) 26 (2.4) Beckmann Accu-cTnI 99.5 (99.0-99.9) 923 (81.9)
ROMI18 1137 Index NSTEMI 133 (11.7) 40 (4.4) Abbott cTnI 99.1 (98.1-99.7) 503 (44.2)
Korley et al24 808 Index type 1 MI 19 (2.4) 4 (0.6) Abbott cTnI 99.4 (98.3-100) 266 (32.9)
ADAPT-C25 1106 Type 1 MI or cardiac
death (30 d)
265 (24.0) 42 (5.0) Abbott cTnI 99.1 (98.0-99.7) 475 (42.9)
ADAPT-RCT26 474 Type 1 MI or cardiac
death (30 d)
75 (15.8) 20 (5.0) Abbott cTnI 99.3 (98.0-100) 228 (48.1)
RING27 144 Index NSTEMI 9 (6.2) 1 (0.8) Roche c-TnT 99.4 (97.8-100) 88 (61.1)
High-Sensitivity Cardiac Troponin T Cohorts
TI-AMO11 1552 Index NSTEMI 90 (5.8) 18 (1.6) Roche hs-cTnT 99.8 (99.2-100) 613 (39.5)
APACE30 2226 Index NSTEMI 399 (17.9) 117 (6.1) Roche hs-cTnT 99.2 (98.6-99.7) 1801 (49.8)
BACC9 1496 Type 1 MI or cardiac
death (30 d)
181 (12.0) 47 (3.9) Roche hs-cTnT 98.9 (97.8-99.6) 567 (37.9)
TRUST8 867 Type 1 MI or cardiac
death (30 d)
66 (7.6) 28 (3.5) Roche hs-cTnT 98.3 (97.2-99.1) 664 (76.6)
Body et al28 229 NSTEMI (30 d) 43 (18.8) 9 (5.0) Roche hs-cTnT 99.0 (96.1-100) 48 (21.0)
Body et al29 180 NSTEMI (30 d) 27 (15.0) 5 (3.4) Roche hs-cTnT 98.4 (95.1-99.9) 93 (51.7)
Summary 22 457 2786 (12.4) 645 (3.5) 99.5 (99.3-99.6) 11 012 (49.0)
Abbreviations: ADAPT, 2-h Accelerated Diagnostic Protocol to Assess Patients
With Chest Pain Symptoms Using Contemporary Troponins as the Only
Biomarker; APACE, Advantageous Predictors of Acute Coronary Syndromes
Evaluation; BACC, Biomarkers in Acute Cardiovascular Care; cTnI, cardiac
troponin I; cTnT, cardiac troponin T; EDACS, Emergency Department
Assessment of Chest Pain Score; High STEACS-P, High-Sensitivity Cardiac
Troponin in the Evaluation of Patients With Suspected Acute Coronary
Syndrome–Pilot; High STEACS-S; High-Sensitivity Cardiac Troponin in the
Evaluation of Patients With Suspected Acute Coronary Syndrome–Substudy;
High STEACS-V; High-Sensitivity Cardiac Troponin in the Evaluation of Patients
With Suspected Acute Coronary Syndrome–Validation; hs, high sensitivity;
IMPACT, Improved Assessment of Chest Pain Trial; MI, myocardial infarction;
NPV, negative predictive value; NSTEMI, non–ST-segment elevationmyocardial
infarction; RCT, randomized clinical trial; RING, Reducing the Time Interval
for Identifying New Guideline; ROMI, Rule Out of Myocardial Infarction;
TRUST, Triage Rule-Out Using High-Sensitivity Troponin; UTROPIA, Use of
Abbott High Sensitivity Cardiac Troponin I Assay in Acute Coronary Syndromes.
a Indicates patients with cardiac troponin concentrations99th percentile
at presentation.
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45.9% of patients as low risk, with 4.4 (95% CI, 3.0-6.0)
false negatives per 1000 patients and a PPV of 24.5% (95%
CI, 20.3%-29.2%). The combination of a cardiac troponin I
concentration of less than 2 ng/L and a nonischemic electro-
cardiogram result gave a similar NPV of 99.9% (95% CI,
98.5%-100%) and a sensitivity of 100% (95% CI, 96.6%-
100%) but identified just 13.1% of patients as low risk, with
4.1 (95% CI, 1.8-7.3) false negatives per 1000 patients and
a lower PPV of 14.2% (95% CI, 11.3%-17.6%).
Discussion
In 19 cohorts across 9 countries and encompassingmore than
22000patients, a cardiac troponin I concentrationof less than
5 ng/L at presentation identified half of all patients with sus-
pected acute coronary syndrome as at low risk of myocardial
infarction or cardiac death at 30 days, with 5 false negatives
per 1000 patients tested.
There are a number of strengths to the analysis. This
was a prespecified systematic review andmeta-analysis that
included individual patient-level data from all cohorts iden-
tified. The findings were consistent across a range of health
care settings and geographic regions with considerable dif-
ferences in the prevalence of myocardial infarction. Indi-
vidual patient-level data were included from more than
22000 patients, allowing a meaningful analysis of impor-
tant subgroups. All studies were prospective, and in all
studies the final diagnosis was adjudicated according to the
universal definition of myocardial infarction.
Two recentmeta-analyses have suggested an approach to
risk stratification using the limit of detection of the high-
sensitivity cardiac troponinTassay,which identifiesup to31%
of patients with an NPV of 99.3%.31,32 The limit of detection
of the high-sensitivity cardiac troponin I assay identifies 19%
to 27% of patients as low risk with an NPV of 99.5% or
greater.8-10 Themajor limitation of this approach for both as-
says is analytical, with biases and analytical variation at the
Figure 2. Negative Predictive Value of an hs-cTnI Concentration of Less Than 5 ng/L at Presentation by Cohort for Primary Outcome (IndexMyocardial
Infarction or Cardiac Death at 30Days) by Assay Used for Adjudication
97 10099
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(95% CI)
9 2283 3781High STEACS-V6 99.6 (99.3-99.8)
cTnI or cTnT assay
0 563 1193Keller et al21 99.9 (99.7-100)
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1 612 1156TI−AMO11 99.8 (99.2-100)
8 1100 1801APACE30 99.2 (98.6-99.7)
6 561 1202BACC9 98.9 (97.8-99.6)
11 653 810TRUST8 98.3 (97.2-99.1)
0 48 179Body et al28 99.0 (96.1-100)
1 92 147Body et al29 98.4 (95.1-99.9)
60 10 952 18 248Summary 99.5 (99.3-99.6)
1 531 720ADAPT−B22 99.7 (99.1-100)
4 919 1083IMPACT23 99.5 (99.0-99.9)
4 499 915ROMI18 99.1 (98.1-99.7)
1 265 636Korley et al24 99.4 (98.3-100)
4 471 838ADAPT−C25 99.1 (98.0-99.7)
1 227 400ADAPT−RCT26 99.3 (98.0-100)
0 88 122RING27 99.4 (97.8-100)
3 771 1326UTROPIA10 99.5 (99.0-99.9)
1 468 828High STEACS-P19 99.7 (99.0-100)
2 426 617High STEACS-S7 99.4 (98.5-99.9)
3 375 494EDACS20 99.1 (97.9-99.8)
Cardiac troponin I
Cardiac troponin T
Datamarkers indicate the central estimate of negative predictive value (NPV)
(orangemarkers for cardiac troponin I [cTnI] and blackmarkers for cardiac troponin
T [cTnT] assays)with size of the datamarkers corresponding to the number of
patients per cohort (large, >3000patients;medium,1000patients; small,
<1000patients) and error bars indicating 95%CIs. Dotted line indicates central
estimate of NPV at 99.5%. ADAPT indicates 2-h AcceleratedDiagnostic Protocol to
Assess PatientsWith Chest Pain SymptomsUsing Contemporary Troponins as the
Only Biomarker; APACE, Advantageous Predictors of Acute Coronary Syndromes
Evaluation; BACC, Biomarkers in Acute Cardiovascular Care; EDACS, Emergency
Department Assessment of Chest Pain Score; High STEACS-P, High-Sensitivity
Cardiac Troponin in the Evaluation of PatientsWith SuspectedAcute Coronary
Syndrome–Pilot; High STEACS-S; High-Sensitivity Cardiac Troponin in the
Evaluation of PatientsWith SuspectedAcute Coronary Syndrome–Substudy;
High STEACS-V; High-Sensitivity Cardiac Troponin in the Evaluation of Patients
With SuspectedAcute Coronary Syndrome–Validation; hs, high sensitivity;
IMPACT, ImprovedAssessment of Chest Pain Trial; RCT, randomized clinical
trial; RING, Reducing the Time Interval for IdentifyingNewGuideline;
ROMI, RuleOut ofMyocardial Infarction; TRUST, Triage Rule-OutUsing
High-Sensitivity Troponin; UTROPIA, Use of Abbott High Sensitivity Cardiac
Troponin I Assay in Acute Coronary Syndromes.
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limitofdetectionassociatedwith ratesofmisclassification that
are twice that observed at 5 ng/L.33,34
In clinical practice, cardiac troponin concentrations are
interpreted in conjunction with the electrocardiogram and
clinical assessment. When a risk stratification threshold of
less than 5 ng/L was evaluated in the subgroup of patients
without myocardial ischemia on electrocardiogram, the
NPV and sensitivity were excellent. To ensure that safety
estimates were conservative, performance was evaluated
not just for an index diagnosis but for a composite end point
that included events up to 30 days. Although there were 81
cardiac deaths at 30 days, none occurred in the 6956
patients with cardiac troponin I concentrations less than
5 ng/L. Furthermore, performance was similar for both
spontaneous type 1 and secondary type 2 myocardial infarc-
tion. This is relevant because the diagnosis of type 2 myo-
cardial infarction is more challenging and is associated with
a worse prognosis.35-37
At a threshold of 5 ng/L, the analytical performance of
the high-sensitivity cardiac troponin I assay is excellent.6,38
The use of lower thresholds did not improve diagnostic
accuracy. A miss rate of 5 per 1000 patients was observed
when applying less than 5 ng/L as the risk stratification
threshold, with a miss rate of 4 per 1000 patients observed
at a threshold of less than 2 ng/L. Although the true risk of
missing an individual patient with myocardial infarction is
the same at both thresholds, lower thresholds reduce the
proportion of patients classified as at low risk; only 1 in 10
patients had a troponin I concentration of less than 2 ng/L
compared with 5 in 10 patients a with concentration of less
than 5 ng/L. Use of lower thresholds would result in more
patients without myocardial infarction being admitted for
serial testing and further investigation, with an increase in
health care expenditures.
Despite recent changes to guidelines,5 the majority of
clinicians continue to rely on the 99th percentile to rule in
and rule out myocardial infarction.39 A pathway incorporat-
ing a risk stratification threshold of less than 5 ng/L along-
side nonischemic electrocardiogram findings misses 5-fold
fewer index myocardial infarctions or 30-day events than
guideline-approved pathways based exclusively on the 99th
percentile.7 This limitation of the 99th percentile has now
been demonstrated in multiple studies.25,40 This approach
to risk stratification using low high-sensitivity cardiac tro-
ponin concentrations has major potential to improve both
the efficiency of health care delivery and patient safety and
is being formally evaluated in a prospective multicenter
clinical trial (NCT03005158).
This study has several limitations. First, not all cohorts
used identical protocols, with differences both in the inclu-
sion criteria and the diagnostic criteria used for adjudication
(eAppendix 3 in the Supplement). However, no significant
differences in NPV were observed when stratified by adjudi-
cating assay, and the NPV was high across individual cohorts,
suggesting that these findings are generalizable. Second, the
percentage of patients who presented early after onset of
Figure 3. Negative Predictive Value of an hs-cTnI Concentration of Less Than 5 ng/L at Presentation for Primary Outcome (IndexMyocardial Infarction
or Cardiac Death at 30Days) by Prespecified Subgroup
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Sex
38 6043 10 920Male 99.4 (99.1-99.6)
22 4909 7328Female 99.6 (99.3-99.8)
Ischemic heart disease
22 1834 3990Knowna 98.8 (98.1-99.3)
31 7035 10 170None known 99.6 (99.4-99.7)
Time from symptom onset to troponin sample collection, h
20 1540 2303≤2b 99 (97.7-99.5)
26 6851 11 101>2 99.6 (99.4-99.8)
Myocardial ischemia on electrocardiogram
15 818 2178Yesc 98.2 (96.4-99.1)
39 8899 13 709No 99.7 (99.4-99.8)
.02
.48
.03
.003
<.001
hs-cTnI indicates high-sensitivity cardiac troponin I; NPV, negative predictive
value. Data markers indicate the central estimate of NPV with size
corresponding to the number of patients per cohort (large, >3000
patients; medium,1000 patients; small, <1000 patients) and error
bars indicating 95% CIs. Dotted line and shaded areas represent
the central estimate and 95% CIs for the full analysis population.
All 19 cohorts were included in analyses unless otherwise specified.
a Ischemic heart disease status available in 16 of 19 cohorts.
b Time from symptom onset to troponin sample collection available in 15
of 19 cohorts.
c Electrocardiogram findings available in 15 of 19 cohorts.
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symptoms was low at just 10% of the study population.
Despite observing an NPV of 99% in this subgroup, inconsis-
tencies in the documentation of symptom onset across
cohorts may affect the analysis, and until further research is
available, serial testing is recommended in patients present-
ing within 2 hours of symptom onset.5 The greatest number
of false negatives was observed in the cohort with the short-
est median symptom onset to sample time (179 [interquartile
range, 119-349] minutes), which may explain the lower NPV
and sensitivity reported at this threshold in a previous
study.8 Third, while it is reassuring that patients with tro-
ponin I concentrations of less than 5 ng/L had a much lower
rate of cardiac death at 1 year than did patients with concen-
trations between 5 ng/L and the 99th percentile, this obser-
vation needs to be verified in prospective studies in which
patient care is guided by this approach.
Figure 4. Optimal Threshold of hs-cTnI at Presentation to Risk-Stratify PatientsWith Suspected Acute Coronary
Syndrome forMyocardial Infarction or Cardiac Death at 30Days
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Electrocardiogram data were not
available for 2929 patients (15.7%).
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Conclusions
Among patients with suspected acute coronary syndrome,
a high-sensitivity cardiac troponin I concentration of less
than 5 ng/L at presentation identified those at low risk
of myocardial infarction or cardiac death within 30
days. Further research is needed to understand the clini-
cal utility and cost-effectiveness of this approach to risk
stratification.
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